Darnatein, OSR Company, Expands IP Protection for Arthritis Tech
09 Apr 2025 //
PR NEWSWIRE
Vaximm AG Announces Phase 2a Trial Results for Glioblastoma
26 Mar 2025 //
PR NEWSWIRE
OSR, SillaJen MOU For US Therapeutic Development
22 Apr 2024 //
PR NEWSWIRE